tiprankstipranks
Company Announcements

Contineum Therapeutics Appoints Diego Miralles to Board

Story Highlights
  • Contineum Therapeutics appointed Diego Miralles to its Board on March 14, 2025.
  • Dr. Miralles’ appointment strengthens the company’s leadership with his extensive industry experience.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

An update from Contineum Therapeutics, Inc. Class A ( (CTNM) ) is now available.

On March 14, 2025, Contineum Therapeutics, Inc. appointed Diego Miralles, M.D. to its Board of Directors as a Class II director, with his term expiring at the 2026 annual meeting of stockholders. Dr. Miralles, who has extensive experience in the pharmaceutical and biotechnology sectors, was previously engaged with the company under an advisor agreement that provided strategic, scientific, and clinical development consulting services. His appointment is part of the company’s ongoing efforts to strengthen its leadership team. Dr. Miralles will receive compensation as a non-employee director, including an initial grant of stock options, and has entered into an indemnification agreement similar to those of other board members.

More about Contineum Therapeutics, Inc. Class A

YTD Price Performance: -53.94%

Average Trading Volume: 80,811

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $172.6M

For a thorough assessment of CTNM stock, go to TipRanks’ Stock Analysis page.

Questions or Comments about the article? Write to editor@tipranks.com

Questions or Comments about the article? Write to editor@tipranks.com
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App